Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Research

• Publication date

  2018-05-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-17-3677PMID 29487201
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.

  2025cited by this paper
• FOXA1 inhibits prostate cancer neuroendocrine differentiation

  2017cited by this paper
• SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.

  2017cited by this paper
• SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer

  2017cited by this paper
• The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

  2017cited by this paper
• Biology and evolution of poorly differentiated neuroendocrine tumors

  2017cited by this paper
• α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies

  2017cited by this paper
• Emerging Variants of Castration-Resistant Prostate Cancer

  2017cited by this paper
• Liquid droplet formation by HP1α suggests a role for phase separation in heterochromatin

  2017cited by this paper
• Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

  2017cited by this paper
• Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

  2017cited by this paper
• Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.

  2017cited by this paper
• Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer

  2016cited by this paper
• Divergent clonal evolution of castration resistant neuroendocrine prostate cancer

  2016cited by this paper
• Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas

  2016cited by this paper
• Downregulation of HP1α suppresses proliferation of cholangiocarcinoma by restoring SFRP1 expression

  2016cited by this paper
• N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.

  2016cited by this paper
• N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.

  2016cited by this paper
• Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).

  2016cited by this paper
• HP1-Assisted Aurora B Kinase Activity Prevents Chromosome Segregation Errors.

  2016cited by this paper
• Prostate cancer

  2016cited by this paper
• Constitutive heterochromatin formation and transcription in mammals

  2015cited by this paper
• EpiFactors: a comprehensive database of human epigenetic factors and complexes

  2015cited by this paper
• Polycomb-mediated silencing in neuroendocrine prostate cancer

  2015cited by this paper
• HP1 is involved in regulating the global impact of DNA methylation on alternative splicing.

  2015cited by this paper
• Chromatin signatures of cancer

  2015cited by this paper
• The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.

  2015cited by this paper
• The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression

  2014cited by this paper
• HP1a: a structural chromosomal protein regulating transcription.

  2014cited by this paper
• High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.

  2014cited by this paper
• Human heterochromatin protein 1 isoforms regulate androgen receptor signaling in prostate cancer.

  2013cited by this paper
• HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response

  2013cited by this paper
• Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas

  2012cited by this paper
• The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer

  2012cited by this paper
• Network Biology of Tumor Stem-like Cells Identified a Regulatory Role of CBX5 in Lung Cancer

  2012cited by this paper
• From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer

  2012cited by this paper
• The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

  2012cited by this paper
• Molecular signatures database (MSigDB) 3.0

  2011cited by this paper
• Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

  2011cited by this paper
• Heterochromatin protein 1 is recruited to various types of DNA damage

  2009cited by this paper
• Heterochromatin protein 1α: a hallmark of cell proliferation relevant to clinical oncology

  2009cited by this paper
• Hematoxylin and eosin staining of tissue and cell sections.

  2008cited by this paper
• The heterochromatin protein 1 family is regulated in prostate development and cancer.

  2008cited by this paper
• Heterochromatin revisited

  2007cited by this paper
• Diagnosis of adenocarcinoma in prostate needle biopsy tissue

  2007cited by this paper
• Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

  2005cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper
• HP1 and the dynamics of heterochromatin maintenance

  2004cited by this paper
• Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.

  2003cited by this paper
• Interaction with members of the heterochromatin protein 1 (HP1) family and histone deacetylation are differentially involved in transcriptional silencing by members of the TIF1 family

  1999cited by this paper
• Mutation in a heterochromatin-specific chromosomal protein is associated with suppression of position-effect variegation in Drosophila melanogaster.

  1990cited by this paper
• Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies.

  1989cited by this paper

• Clonal selection of pre-existing neuroendocrine component in prostate cancer during androgen receptor signaling inhibitor therapy: A case report

  2026cites this paper
• Widespread activation and critical role of EMT and stemness in the neuroendocrine differentiation of prostate cancer (Review)

  2025cites this paper
• New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic

  2025cites this paper
• Advancing therapeutics in small-cell lung cancer

  2025cites this paper
• Translating G9a epigenetics' role: From cell machinery to cancer therapy.

  2025cites this paper
• Unravelling the impact of the chromobox proteins in human cancers

  2025cites this paper
• The molecular pathogenesis of SOX2 in prostate cancer

  2025cites this paper
• Exploring B7-H4's role in prostate cancer dormancy post-androgen deprivation therapy: extracellular matrix interactions and therapeutic opportunities.

  2025cites this paper
• Longitudinal single-cell analysis reveals RUNX1T1 as an early driver in treatment-induced neuroendocrine transdifferentiation

  2025cites this paper
• PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility

  2024cites this paper
• ID2 Promotes Lineage Transition of Prostate Cancer through FGFR and JAK-STAT Signaling

  2024cites this paper
• Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review

  2024cites this paper
• Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer

  2024cites this paper
• Deciphering Complexity: The Molecular Landscape of Castration-Resistant Prostate Cancer.

  2024cites this paper
• Epigenetic regulation of neuroendocrine prostate cancer

  2024cites this paper
• Understanding the molecular regulators of neuroendocrine prostate cancer.

  2024cites this paper
• Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression

  2024cites this paper
• G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications

  2024cites this paper
• Unveiling the role of HP1α-HDAC1-STAT1 axis as a therapeutic target for HP1α-positive intrahepatic cholangiocarcinoma

  2024cites this paper
• Systemic metastases in large cell neuroendocrine prostate cancer: a rare case report and literature review

  2024cites this paper
• Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer

  2023cites this paper
• Epigenetic (De)regulation in Prostate Cancer.

  2023cites this paper
• Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer

  2023cites this paper
• Neurokinin-1 receptor drives PKCɑ-AURKA/N-Myc signaling to facilitate the neuroendocrine progression of prostate cancer

  2023cites this paper
• HP1α promotes the progression of prostate cancer

  2023cites this paper
• Epigenetics-based diagnostic and therapeutic strategies: shifting the paradigm in prostate cancer.

  2023cites this paper
• BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer

  2023cites this paper
• Chromobox proteins in cancer: Multifaceted functions and strategies for modulation (Review)

  2023cites this paper
• AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer

  2023cites this paper
• Zinc-Loaded Black Phosphorus Multifunctional Nanodelivery System Combined With Photothermal Therapy Have the Potential to Treat Prostate Cancer Patients Infected With COVID-19

  2022cites this paper
• Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications

  2022cites this paper
• Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation

  2022cites this paper
• H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer

  2022cites this paper
• Molecular Mechanisms Underlying the Development of Neuroendocrine Prostate Cancer.

  2022cites this paper
• Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression

  2022cites this paper
• Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

  2022cites this paper
• The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer

  2021cites this paper
• Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses

  2021cites this paper
• Patient-derived xenograft models of neuroendocrine prostate cancer.

  2021cites this paper
• Molecular events in neuroendocrine prostate cancer development

  2021cites this paper
• University ’ s repository of research publications and other research outputs The Open University ’ s first one day symposium on treatment-emergent neuroendocrine prostate cancer Conference or Workshop Item

  2021cites this paper
• The evolutionarily conserved long non‐coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms

  2021cites this paper
• ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development

  2021cites this paper
• Epigenetic Regulatory Enzymes: mutation Prevalence and Coexistence in Cancers

  2021cites this paper
• Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.

  2021cites this paper
• Doxorubicin-loaded Black Phosphorus Multifunctional Nanodelivery System Combined With Photothermal Therapy Promotes Immunogenic Death of Prostate Cancer PC-3 cells.

  2021cites this paper
• Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review.

  2020cites this paper
• Proline-rich 11 (PRR11) drives F-actin assembly by recruiting the actin-related protein 2/3 complex in human non-small cell lung carcinoma

  2020cites this paper
• Epigenetic modulations and lineage plasticity in advanced prostate cancer.

  2020cites this paper
• The Open University's first one-day symposium on treatment-emergent neuroendocrine prostate cancer.

  2020cites this paper
• LIN28B promotes the development of neuroendocrine prostate cancer.

  2020cites this paper
• Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development

  2020cites this paper
• Identifying Potential Off-Target Protein Binders of Glutamate-Ureido-Lysine, a Prostate Cancer Specific Imaging Agent

  2020cites this paper
• A Screening Method for Identification of Heterochromatin-Promoting Drugs Using Drosophila.

  2020cites this paper
• Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.

  2019cites this paper
• SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer

  2019cites this paper
• Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines

  2019cites this paper
• MicroRNA-194 promotes lineage plasticity in advanced prostate cancer

  2019cites this paper
• hnRNPM, a potential mediator of YY1 in promoting the epithelial-mesenchymal transition of prostate cancer cells.

  2019cites this paper
• Human rDNA Copy Number Is Unstable in Metastatic Breast Cancers

  2019cites this paper
• Regulation of centromeric heterochromatin in the cell cycle by phosphorylation of histone H3 tyrosine 41

  2019cites this paper
• Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms

  2019cites this paper
• Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells

  2019cites this paper
• CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma1

  2018cites this paper
• Prostate cancer: A novel mechanism of neuroendocrine transdifferentiation

  2018cites this paper
• The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications

  2018cites this paper
• Using NEPC cell NCI-H660 for in vitro assays

  2018cites this paper